GC Pharma Confirms Phase 2/3 Clinical Trial of New Protein Therapy for Hepatitis B
GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced that it will proceed with a Phase 2/3 c...
Continue Reading →
